A5349: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial (TBTC S31)

Study Location:

India

Topic:

Tuberculosis and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/record/NCT02410772?term=A5349&rank=1

IRB#:

IRB00090100

Coordinator:

Nishi Suryavanshi

Enrollment:

Open

Trial Period:

Ongoing

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week, with direct observation of each dose by a health-care worker at least five of the seven days of each week.

Ages Eligible for Study: 12 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Nishi Suryavanshi
nishisuryavanshi@hotmail.com

Categories

Location
Topic

Clinical Trials

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5346: Sitagliptin for Reducing Inflammation and Immune...

The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin)...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More